ML261 CAR T Cell Therapy for Small Cell Lung Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This is a first-in-human (FIH), open-label, Phase 1 study designed to evaluate the safety, pharmacokinetics (PK), and preliminary efficacy of ML261, an autologous potency enhanced anti-DLL3 CAR T cell therapy, in participants with R/R SCLC or select NECs
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive ML261, an autologous potency enhanced anti-DLL3 CAR T cell therapy
DLT Observation
Participants are monitored for dose-limiting toxicities (DLTs)
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- ML261
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
DLL3-Directed Chimeric Antigen Receptor T cells (CAR T)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Moonlight Bio, Inc
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.